It was recently revealed that Immune Pharmaceuticals Inc (NASDAQ:IMNP), will be announcing the official release of their drug Remain, which was developed, with the intention to aid those suffering from acute Myeloid Leukaemia.
However, this is mainly developed to aid with remission maintenance, as well as in order to diminish the chances of the body going through a relapse, and beginning the illness from the beginning. According to release notes of the company, it is expected that patient recruitment will begin in 2017.
The success of Remain against Acute Myeloid Leukaemia
Although it is true that this drug will have a significant impact on the Nasdaq stocks of this company, from the results, which this drug has offered, it seems that this may be a viable, and efficient treatment options, for those who are suffering from this disease.
The drug itself has already been approved throughout Europe, as well as in Israel. The reason behind this approval, according to those well-versed in the matter, was due to the success, which the drug illustrated through its Phase III clinical trials.
However, the testing for the United States region is far from over, with the U.S Food and Health administration, even offering Immune a helping hand. Following the advice was given, the company announced that over the next year they would be working on recruiting over 400 patients.
The reason why Immune will be recruiting patients for their drug Remain
This may seem absurd considering the company, has announced that Remain will be available. However, The company is still working on evaluating the endpoint for overall survival, amongst patients, who implement this drug into their treatment regime.
In addition to this, the company announced that they wished to better determine the endpoint for Leukaemia-free survival, over a one-year period span. These two tests are the reasons to why the drug has yet to be announced with an official date for this coming year.